Research: CANCER Folding Project #18707

From https://www.tandfonline.com/doi/full/10.1080/1744666X.2022.2050596: "Dysregulation of JAK signaling is a feature of many diseases.

Targeting the JAK pathway started out as a therapeutic option in the field of myeloproliferative disorders.

The JAK2 Val617Phe mutation, which results in constitutive activation of the pathway, is found in over 50% of individuals with myelofibrosis and essential thrombocythaemia, and almost 100% of patients with polycythemia vera [5,6].

Ruxolitinib, a JAK1/JAK2 inhibitor, was the first JAK inhibitor approved for clinical use to treat myelofibrosis in 2011." Starting from an AlphaFold structure of the JAK2 mutant, In these projects were are generating data to aid virtual screening efforts for new (more selective) inhibitors, as well as conducting small molecule fragment screens to find potential starting points for design efforts (which are being shared with all of you in real time, and will be summarized regularly).

This is a project run by Roivant Sciences (formerly Silicon Therapeutics) as was officially announced in this press release: https://foldingathome.org/2021/04/20/maximizing-the-impact-of-foldinghome-by-engaging-industry-collaborators/ All data is being made publicly available as soon as it is received at https://console.cloud.google.com/storage/browser/stxfah-bucket.